US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Achieve Life Sciences
Achieve Life Sciences Announces Refresh to Board of Directors
March 30, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
March 29, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
March 03, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
March 02, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
February 07, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Granting of New Hire Inducement Award
January 27, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Granting of New Hire Inducement Award
March 17, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
March 08, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference
February 02, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
January 09, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
December 21, 2022
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences Announces Private Placement of $18.9 Million
November 15, 2022
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
November 08, 2022
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
October 31, 2022
From
Achieve Life Sciences
Via
GlobeNewswire
Tickers
ACHV
